Tubulin polymerization-IN-94
Tubulin polymerization-IN-94 is a tubulin polymerization inhibitor. Tubulin polymerization-IN-94 inhibits tubulin polymerization, forms a hydrogen bond with β-Asn349, and exhibits π-stacking with β-Lys352. Tubulin polymerization-IN-94 shows potent antiproliferative activity against multiple cancer cell lines. Tubulin polymerization-IN-94 induces G2/M cell cycle arrest, apoptosis, and disruption of the microtubule network. Tubulin polymerization-IN-94 can be used in research related to cervical cancer, gastric cancer, and breast cancer.
For research use only. We do not sell to patients.
- Formula: C22H19N5O3
- Molecular Weight:401.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
0.13 μM
|
Antiproliferative activity against human HeLa cervical carcinoma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human HeLa cervical carcinoma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
42621831 |
| SGC-7901 | IC50 |
0.15 μM
|
Antiproliferative activity against human SGC-7901 gastric carcinoma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human SGC-7901 gastric carcinoma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
42621831 |
| MCF7 | IC50 |
0.18 μM
|
Antiproliferative activity against human MCF-7 breast carcinoma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human MCF-7 breast carcinoma cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
42621831 |
| HUVEC | IC50 |
4.5 μM
|
Cytotoxicity against normal human umbilical vein endothelial cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Cytotoxicity against normal human umbilical vein endothelial cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
42621831 |
In Vitro
Tubulin polymerization-IN-94 (Compound 10t) (0-100 μM; 72 h) exhibits potent antiproliferative activity against HeLa, SGC-7901, and MCF-7 cancer cell lines with IC50 values of 0.13, 0.15, and 0.18 μM, respectively, and shows good cancer cell selectivity with low cytotoxicity against normal HUVECs[1].
Tubulin polymerization-IN-94 (3 μM; 0-60 min) acts as a potent microtubule destabilizer by inhibiting tubulin polymerization[1].
Tubulin polymerization-IN-94 binds to the colchicine site of tubulin with a docking score of −10.467 and forms a unique hydrogen bond with β-Asn349, which is not observed for CA-4 or compound 7[1].
Tubulin polymerization-IN-94 (100 ns) forms a dynamically stable complex with tubulin at the colchicine binding site, with low ligand RMSD and stable protein conformation[1].
Tubulin polymerization-IN-94 complies with Lipinski's rule and exhibits favorable drug-like properties, suggesting potential oral bioavailability[1].
Tubulin polymerization-IN-94 (130 nM; 24 h) effectively disrupts microtubule stability and interferes with normal mitotic progression in HeLa cells, inducing microtubule depolymerization, nuclear condensation, and multinucleation[1].
Tubulin polymerization-IN-94 (65-260 nM; 24 h) effectively disrupts normal mitotic progression in HeLa cells by inducing dose-dependent G2/M phase arrest[1].
Tubulin polymerization-IN-94 (65-260 nM; 48 h) efficiently induces apoptosis in HeLa cervical cancer cells in a dose-responsive manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HeLa
-
Concentration:130 nM
-
Incubation Time:24 h
-
Result:Caused pronounced disruption of the microtubule network.
The filamentous structures broke down and collapsed, giving rise to dense, perinuclear aggregates surrounding the nucleus.
Marked nuclear pyknosis, indicative of chromatin condensation, along with the emergence of multinucleated cells, was clearly observed.
-
Cell Line:HeLa
-
Concentration:65, 130 and 260 nM
-
Incubation Time:24 h
-
Result:Induced a dose-dependent and marked accumulation of cells within the G2/M phase.
The percentage of cells arrested at G2/M rose from 4.05% in the vehicle control group to as high as 80.69% at the highest tested concentration.
-
Cell Line:HeLa
-
Concentration:65, 130 and 260 nM
-
Incubation Time:48 h
-
Result:Induced a marked, concentration-dependent increase in apoptosis.
At 65 nM, total apoptosis rate was 4.9% (0.5% early, 4.4% late), with 2.2% necrosis and 92.9% viable cells.
At 130 nM, total apoptosis increased to 8.6% (2.3% early, 6.3% late), with 5.2% necrosis and 86.2% viable cells.
At 260 nM, total apoptosis reached 18.5% (5.5% early, 13.0% late), with 4.4% necrosis and 77.1% viable cells.
Chemical Information
-
Molecular Weight 401.42
-
Formula C22H19N5O3
-
SMILES
COC(C(OC)=C1)=C(OC)C=C1N2N=CC3=NC=C(C4=CC=CC5=C4C=CN5)N=C32
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)